ProQR Therapeutics N.V. (NASDAQ: PRQR) today announced results from a planned interim analysis of its Phase 1/2 trial of QR-110 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments

ProQR (PRQR) Prices 5.75M Share Common Offering at $15.75/ShSeptember 7, 2018 5:45 AM ProQR (PRQR) Announces Proposed $75M Public Share OfferingSeptember 5, 2018 4:02 PM ProQR Therapeutics N.V. (PRQR) PT Raised to $21 at Chardan Capital MarketsSeptember 5, 2018 2:42 PM ProQR Announces Positive Interim Results from Phase 1/2 Clinical Trial of QR-110 in LCA10 Patients, and Plans to Start a Phase 2/3 Pivotal TrialSeptember 5, 2018 4:00 AM